The Manufacturers Life Insurance Company Acquires 267,990 Shares of Moderna, Inc. (NASDAQ:MRNA)

The Manufacturers Life Insurance Company raised its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,341,924 shares of the company's stock after acquiring an additional 267,990 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.87% of Moderna worth $138,957,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB boosted its position in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna in the fourth quarter valued at about $37,000. Crowley Wealth Management Inc. bought a new position in shares of Moderna during the fourth quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Down 5.3 %

Shares of MRNA traded down $1.51 during midday trading on Thursday, hitting $27.03. The company's stock had a trading volume of 14,884,237 shares, compared to its average volume of 7,430,150. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47. The company's fifty day simple moving average is $29.77 and its two-hundred day simple moving average is $38.02. The stock has a market capitalization of $10.45 billion, a price-to-earnings ratio of -2.91 and a beta of 2.23.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company's revenue for the quarter was down 35.3% compared to the same quarter last year. During the same quarter last year, the company posted ($3.07) EPS. On average, research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of research reports. The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Barclays cut Moderna from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Morgan Stanley reduced their price target on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Leerink Partners reduced their price target on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research report on Thursday, January 16th. Finally, UBS Group cut their price objective on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research report on Wednesday, February 19th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.